Health and Human Services Secretary Robert F. Kennedy Jr. on Tuesday rolled out a federal push aimed at reducing the use of certain psychiatric drugs, framing the move as part of a broader effort to address what he described as overprescribing in the U.S. mental health system.
Kennedy Pushes For Deprescribing
Speaking at a mental health summit hosted by the Make America Healthy Again Institute, Kennedy said the initiative would promote “deprescribing,” or the supervised reduction or discontinuation of medications, particularly among children, according to The Hill report.
“Today, we take clear and decisive action to confront our nation’s mental health crisis by addressing the overuse of psychiatric medications,” he said. The initiative will prioritize “patient autonomy,” along with “informed consent and shared decision-making,” while trying to move care toward “prevention, transparency and a more holistic approach to mental health,” Kennedy said.
U.S. Drugmakers Behind Psychiatric Drugs
The FDA approvals for these drugs over the past few years underscore the ongoing conversation about mental health treatment. Among some, Johnson & Johnson (NYSE:JNJ) has secured FDA approval in January 2025 for expanded use of its
This post was originally published here
